MAPK3 and cancer: PARK7, originally identified as a novel oncogene [60], protects cancer cells against oxidative stress, mediating cell survival and proliferation by activating the extracellular signal-regulated kinase (ERK1/2) pathway, and attenuating cell death signaling by inhibiting apoptosis signal-regulating kinase 1 (ASK1) activation [61].